The in vitro production of
interferon (IFN)-gamma,
interleukin (IL)-5, tumour
necrosis factor (
TNF)-alpha and
IL-10 by blood mononuclear cells in response to whole Mycobacterium leprae and polyclonal stimulii of 23 individuals, representing a variety of conditions in relation to exposure/susceptibility to M. leprae, was assayed. In most cases, healthy household contacts of newly diagnosed
multibacillary leprosy patients, designated exposed household contacts (EC), showed low-to-undetectable in vitro IFN-gamma production in addition to substantial
TNF-alpha production in response to M. leprae. In contrast, peripheral blood mononuclear cells from previously exposed contacts (R) regarded as resistant-to-
leprosy released low-to-moderate levels of IFN-gamma together with a mixed
cytokine profile resembling a T helper (Th)0-type response.
TNF-alpha/IL-10 ratios in response to M. leprae and
Concanavalin A were significantly higher in EC than in R contacts suggesting a role for the
TNF-alpha/IL-10 ratio in restraining mycobacteria proliferation and spreading early in
infection. The
cytokine profiles of
leprosy patients were taken as reference points. Post-treatment
lepromatous leprosy patients secreted relatively high levels of
IL-10 in response to M. leprae, whereas one self-cured
tuberculoid leprosy patient produced simultaneously high levels of IFN-gamma and
TNF-alpha. In addition, the quantitative changes in the
cytokines released by peripheral blood mononuclear cells in EC contacts after Bacille Calmette-Guérin (BCG) vaccination were investigated. Vaccination induced amplification of IFN-gamma production with a concomitant decrease in
TNF-alpha/IL-10 ratios that resembled the
cytokine pattern observed in R contacts. IFN-gamma production was observed in response to both a cross-reactive
antigen (
Ag 85) and a M. leprae-specific
protein (
MMP-I), which attests to a BCG nonspecific stimulation of the immune system, thereby casting these
antigens as likely candidates for inclusion in a
subunit vaccine against
leprosy. Finally, a model for protective x pathologic response to mycobacteria is presented.